Isolated unilateral absence of the right pulmo nary artery.

A 40-year-old man was referred for evaluation of cough of a few weeks duration and a history of recurrent respiratory tract infections for several years. Clinical examination revealed no abnormalities. Routine hematologic and biochemical evaluation were normal. Contrast-enhanced computed tomography of the thorax showed a hypoplastic right lung, hyperinflation of the left lung with cardiomediastinal shift to the right. Absence of the right pulmonary artery was noted and replaced by an extensive collateral network of hypertrophied vessels originating from bronchial, intercostal and mammaria interna arteries, and right arteria subclavia (Fig. A, B). Discrete bronchiectasis with thickened bronchial walls in a hypoplastic right lung was noted (Fig. C). A normal bronchial tree and normal parenchyma in the left lung was seen

Integrated plasma proteomic and single-cell immune signaling network signatures demarcate mild, moderate, and severe COVID-19

The biological determinants underlying the range of coronavirus 2019 (COVID-19) clinical manifestations are not fully understood. Here, over 1,400 plasma proteins and 2,600 single-cell immune features comprising cell phenotype, endogenous signaling activity, and signaling responses to inflammatory ligands are cross-sectionally assessed in peripheral blood from 97 patients with mild, moderate, and severe COVID-19 and 40 uninfected patients. Using an integrated computational approach to analyze the combined plasma and single-cell proteomic data, we identify and independently validate a multi-variate model classifying COVID-19 severity (multi-class area under the curve [AUC]training = 0.799, p = 4.2e-6; multi-class AUCvalidation = 0.773, p = 7.7e-6). Examination of informative model features reveals biological signatures of COVID-19 severity, including the dysregulation of JAK/STAT, MAPK/mTOR, and nuclear factor κB (NF-κB) immune signaling networks in addition to recapitulating known hallmarks of COVID-19. These results provide a set of early determinants of COVID-19 severity that may point to therapeutic targets for prevention and/or treatment of COVID-19 progression

Vitamin C as prophylaxis and adjunctive medical treatment for COVID-19?

Severe acute respiratory syndrome coronavirus 2 causes the potentially fatal coronavirus disease 2019 (COVID-19). Already during the outbreak of the severe acute respiratory syndrome coronavirus 1, the use of vitamin C was suggested. Many patients with severe COVID-19 have elevated levels of the mediators interleukin-6 and endothelin-1. These mediators may explain the age dependence of COVID-19 pneumonia, the preponderance of male and obese or hypertensive patients, as well as of persons of color and smokers. There is clear evidence that vitamin C in high doses can reduce these mediators. Vitamin C is cheap and safe. Hence, using a relatively low dose of vitamin C as prophylaxis, and in cases of severe COVID-19, an (intravenous) high-dose regimen may be beneficial. Ongoing clinical trials are expected to provide more definitive evidence.status: Published onlin

Striking essential oil: tapping into a largely unexplored source for drug discovery

Essential oils (EOs) have been used therapeutically for centuries. In recent decades, randomized controlled (clinical) trials have supported efficacy in specific therapeutic indications for a few of them. Some EOs, their components or derivatives thereof have been approved as drugs. Nevertheless, they are still considered products that are mainly used in complementary and alternative medicine. EO components occupy a special niche in chemical space, that offers unique opportunities based on their unusual physicochemical properties, because they are typically volatile and hydrophobic. Here we evaluate selected physicochemical parameters, used in conventional drug discovery, of EO components present in a range of commercially available EOs. We show that, contrary to generally held belief, most EO components meet current-day requirements of medicinal chemistry for good drug candidates. Moreover, they also offer attractive opportunities for lead optimization or even fragment-based drug discovery. Because their therapeutic potential is still under-scrutinized, we propose that this be explored more vigorously with present-day methods.status: publishe

Inhibitory Activity of Essential Oils against Vibrio campbellii and Vibrio parahaemolyticus.

Vibriosis, caused by Vibrio strains, is an important bacterial disease and capable of causing significant high mortality in aquatic animals. Essential oils (EOs) have been considered as an alternative approach for the treatment of aquatic bacterial diseases. In this study, we evaluated the antibacterial activity of essential oils (n = 22) or essential oil components (EOCs, n = 12) against Vibrio strains belonging to the harveyi clade. It was verified by three different approaches, e.g., (i) a bacterial growth assay, comparing Vibrio growth with or without EO(C)s at various concentrations; (ii) a vapor-phase-mediated susceptibility assay, comparing the effect of EO(C)s on bacterial growth through the vapor phase; and (iii) a quorum sensing-inhibitory assay, based on specific inhibition of quorum sensing-regulated bioluminescence. The results showed that, in the bacterial growth assay, EOs of Melaleuca alternifolia and Litsea citrata at 0.0001%, Eucalyptus citriodora at 0.01% can inhibit the growth of Vibrio campbellii BB120. These EOs can also prevent the growth of V. parahaemolyticus strains but need to be present at a higher concentration (0.1%). Moreover, in the vapor-phase-mediated susceptibility assay, EOs of M. alternifolia, L. citrata and E. citriodora can inhibit the growth of V. campbellii BB120 through their vapor phase. However, V. parahaemolyticus strains (CAIM170, LMG2850 and MO904) cannot be inhibited by these EOs. Additionally, in the quorum sensing-inhibitory assay, EOs of Mentha pulegium, Cuminum cyminum, Zingiber officinalis, and E. citriodora, all at 0.001%, have quorum sensing-inhibitory activity in V. campbellii BB120. Taken together, our study provides substantial evidence that usage of the major components, individually or in combination, of the tested commercial EOs (extracted from M. alternifolia, L. citrata, and E. citriodora) could be a promising approach to control V. campbellii BB120.status: Published onlin